[Skip to Navigation]
Sign In

September 2021 - April 2015

Decade

Year

Issue

September 2017, Vol 3, No. 9, Pages 1157-1287

Original Investigation

Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer

Abstract Full Text
open access
JAMA Oncol. 2017;3(9):1190-1196. doi:10.1001/jamaoncol.2017.0424

This case-control study evaluates pathogenic variants in panel genes tested in women with breast cancer.

Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial

Abstract Full Text
free access
JAMA Oncol. 2017;3(9):1197-1203. doi:10.1001/jamaoncol.2016.6762

This study examines the association among mismatch repair deficiency, microsatellite instability, and survival in patients with resectable gastroesophageal cancer randomized to surgery alone or perioperative chemotherapy.

Clinical Characterization of the Pheochromocytoma and Paraganglioma Susceptibility Genes SDHA, TMEM127, MAX, and SDHAF2 for Gene-Informed Prevention

Abstract Full Text
free access
JAMA Oncol. 2017;3(9):1204-1212. doi:10.1001/jamaoncol.2017.0223

This longitudinal registry study assesses the clinical spectra and age-related penetrance in individuals with pheochromocytomas and paragangliomas and mutations in the SDHA, TMEM127, MAX, and SDHAF2 genes.

Patients’ and Parents’ Needs, Attitudes, and Perceptions About Early Palliative Care Integration in Pediatric Oncology

Abstract Full Text
free access
JAMA Oncol. 2017;3(9):1214-1220. doi:10.1001/jamaoncol.2017.0368

This survey evaluates pediatric patients’ and parents’ perceptions of symptom burden during early cancer treatment and assesses their attitudes toward early integration of palliative care in pediatric oncology.

Metronomic Chemotherapy vs Best Supportive Care in Progressive Pediatric Solid Malignant Tumors: A Randomized Clinical Trial

Abstract Full Text
free access
JAMA Oncol. 2017;3(9):1222-1227. doi:10.1001/jamaoncol.2017.0324

This randomized clinical trial compares the effects of metronomic chemotherapy on progression-free survival vs placebo in pediatric patients with primary extracranial, nonhematopoietic solid malignant tumors that progress after at least 2 lines of chemotherapy.

Population-Attributable Risk Proportion of Clinical Risk Factors for Breast Cancer

Abstract Full Text
free access
JAMA Oncol. 2017;3(9):1228-1236. doi:10.1001/jamaoncol.2016.6326

This population-based, case-control, cohort study uses data from the Breast Cancer Surveillance Consortium to assess risk factors associated with breast cancer in premenopausal and postmenopausal women.

Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial

Abstract Full Text
free access
JAMA Oncol. 2017;3(9):1237-1244. doi:10.1001/jamaoncol.2017.0515

This phase 2 trial assesses the effect of neoadjuvant chemotherapy followed by surgery on survival in patients with metastatic gastric and gastroesophageal junction cancer.

Use of Bayesian Decision Analysis to Minimize Harm in Patient-Centered Randomized Clinical Trials in Oncology

Abstract Full Text
free access online only
JAMA Oncol. 2017;3(9):e170123. doi:10.1001/jamaoncol.2017.0123

This study analyzes how patient preferences and burden of disease can be incorporated into randomized clinical trials in oncology using Bayesian decision analysis and the impact that these factors have on statistical thresholds for drug approval.

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study

Abstract Full Text
free access online only
JAMA Oncol. 2017;3(9):e172411. doi:10.1001/jamaoncol.2017.2411

This phase 1/2 open-label study reports a planned update of the safety and efficacy of durvalumab in patients with locally advanced/metastatic urothelial carcinoma who had progressed on, were ineligible for, or refused prior chemotherapy.

Brief Report

Association Between Loss-of-Function Mutations Within the FANCM Gene and Early-Onset Familial Breast Cancer

Abstract Full Text
free access
JAMA Oncol. 2017;3(9):1245-1248. doi:10.1001/jamaoncol.2016.5592

This case-control study analyzed the entire coding region of the FANCM gene to find its association with breast and ovarian cancer risk.

Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial

Abstract Full Text
free access
JAMA Oncol. 2017;3(9):1249-1252. doi:10.1001/jamaoncol.2017.0076

This updated analysis of a subset in the ASSURE clinical trial examines the disease-free survival and overall survival of high-risk patients with clear cell renal cancer treated with sunitinib, sorafenib, or placebo.

Clinical and Radiologic Responses to Cladribine for the Treatment of Erdheim-Chester Disease

Abstract Full Text
free access
JAMA Oncol. 2017;3(9):1253-1256. doi:10.1001/jamaoncol.2017.0041

This medical record review assesses the clinical and radiologic responses to cladribine for the treatment of adults with Erdheim-Chester disease.

Research Letter

Lung Cancer Screening With Low-Dose Computed Tomography in the United States—2010 to 2015

Abstract Full Text
free access
JAMA Oncol. 2017;3(9):1278-1281. doi:10.1001/jamaoncol.2016.6416

This study examines whether low-dose computed tomography screening for lung cancer increased following the United States Preventive Services Task Force recommendations.

Association of Interactive Reminders and Automated Messages With Persistent Adherence to Colorectal Cancer Screening: A Randomized Clinical Trial

Abstract Full Text
free access
JAMA Oncol. 2017;3(9):1281-1283. doi:10.1001/jamaoncol.2017.1062

This study examines the effectiveness of interactive telephone calls vs automated short message service on improving adherence to fecal immunochemical test screening compared with usual care.

Special Communication

Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016

Abstract Full Text
JAMA Oncol. 2017;3(9):1257-1265. doi:10.1001/jamaoncol.2016.5763

This Special Communication provides consensus recommendations for a risk-adapted approach to treatment of Waldenström macroglobulinemia.

Review

Androgen Receptor Function and Androgen Receptor–Targeted Therapies in Breast Cancer: A Review

Abstract Full Text
JAMA Oncol. 2017;3(9):1266-1273. doi:10.1001/jamaoncol.2016.4975

This review examines androgen receptor (AR)-related pathways, specific AR-targeted therapies, and the development of predictive biomarkers to stratify patients by likelihood of response to AR-targeted therapies.

JAMA Oncology Clinical Evidence Synopsis

Targeted Therapy as an Alternative to Whole-Brain Radiotherapy in EGFR-Mutant or ALK-Positive Non–Small-Cell Lung Cancer With Brain Metastases

Abstract Full Text
JAMA Oncol. 2017;3(9):1274-1275. doi:10.1001/jamaoncol.2017.1047

This Clinical Evidence Synopsis summarizes 3 randomized clinical trials that compare whole-brain radiotherapy with highly active targeted therapies in patients with non–small-cell lung cancer with brain metastases.

JAMA Oncology Clinical Challenge

Expanding Purpura in a Neutropenic Patient

Abstract Full Text
JAMA Oncol. 2017;3(9):1276-1277. doi:10.1001/jamaoncol.2017.0781

A man in his 40s with newly diagnosed acute myelogenous leukemia arising from myelodysplasia presented with fever, cough, abdominal pain, difficulty swallowing, and 1 month of neutropenia. What is your diagnosis?

Viewpoint

The High Cost of New Cancer Therapies—A Challenge of Inequality for All Countries

Abstract Full Text
JAMA Oncol. 2017;3(9):1169-1170. doi:10.1001/jamaoncol.2016.6335

This Viewpoint describes the high cost of new cancer therapies, making comparisons to the early years of the AIDS epidemic, when many patients in low-resource countries died because of the initial high cost of HIV medications.

Is There Room for Second-Line Treatment of Pleural Malignant Mesothelioma?

Abstract Full Text
free access
JAMA Oncol. 2017;3(9):1170-1171. doi:10.1001/jamaoncol.2016.6135

This Viewpoint discusses the uncertain evidence for second-line treatment of pleural malignant mesothelioma.

Treatment of Gastric and Gastroesophageal Cancers—Do We Really Need Anthracyclines?

Abstract Full Text
JAMA Oncol. 2017;3(9):1172-1173. doi:10.1001/jamaoncol.2016.3064

This Viewpoint questions the use of anthracyclines in the treatment of gastroesophageal cancers.

Editorial

Multigene Panel Testing and Breast Cancer Risk: Is It Time to Scale Down?

Abstract Full Text
JAMA Oncol. 2017;3(9):1176-1177. doi:10.1001/jamaoncol.2017.0342

Planning Adjuvant Trials When Regimens Effective for Patients With Advanced Disease Don’t Work in the Adjuvant Setting—Paradigms Lost

Abstract Full Text
JAMA Oncol. 2017;3(9):1178-1179. doi:10.1001/jamaoncol.2017.0066
Invited Commentary

Pheochromocytoma and Paraganglioma Susceptibility Genes: Estimating the Associated Risk of Disease

Abstract Full Text
JAMA Oncol. 2017;3(9):1212-1213. doi:10.1001/jamaoncol.2017.0222

Pediatric Palliative Care—A Shared Priority

Abstract Full Text
JAMA Oncol. 2017;3(9):1220-1221. doi:10.1001/jamaoncol.2017.0351
Cancer Care Chronicles

Escalation of Commitment in Treatment Decisions Near the End of Life

Abstract Full Text
JAMA Oncol. 2017;3(9):1174-1175. doi:10.1001/jamaoncol.2016.5490
Poetry and Oncology

Sickness

Abstract Full Text
JAMA Oncol. 2017;3(9):1287. doi:10.1001/jamaoncol.2017.0476
Comment & Response

Current Challenges Associated With Next-Generation Sequencing of Breast Cancer

Abstract Full Text
JAMA Oncol. 2017;3(9):1283-1284. doi:10.1001/jamaoncol.2017.0659

Erroneous Sentence in Cancer Care Chronicles Article

Abstract Full Text
JAMA Oncol. 2017;3(9):1283. doi:10.1001/jamaoncol.2017.1363

Mutation in BRAF V600E: A Poor Prognostic Marker in Stage III Colon Cancers With Deficient MMR?

Abstract Full Text
JAMA Oncol. 2017;3(9):1284-1285. doi:10.1001/jamaoncol.2017.0262

Current Challenges Associated With Next-Generation Sequencing of Breast Cancer—Reply

Abstract Full Text
JAMA Oncol. 2017;3(9):1284. doi:10.1001/jamaoncol.2017.0665

Mutation in BRAF V600E: A Poor Prognostic Marker in Stage III Colon Cancers With Deficient MMR?—Reply

Abstract Full Text
JAMA Oncol. 2017;3(9):1285-1286. doi:10.1001/jamaoncol.2017.1474
Correction

Erroneous Sentence Removed From Article

Abstract Full Text
free access
JAMA Oncol. 2017;3(9):1286. doi:10.1001/jamaoncol.2017.1368

Error in Author Degree

Abstract Full Text
free access
JAMA Oncol. 2017;3(9):1286. doi:10.1001/jamaoncol.2017.2031

Error in Figure

Abstract Full Text
free access
JAMA Oncol. 2017;3(9):1286. doi:10.1001/jamaoncol.2017.3416
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2017;3(9):1159. doi:10.1001/jamaoncol.2016.4458
In This Issue of JAMA Oncology

Highlights

Abstract Full Text
free access
JAMA Oncol. 2017;3(9):1157. doi:10.1001/jamaoncol.2016.4457
×